Kala Bio, INC. 8-K Filing

FAQ

Key Financial Figures

• $0.001 — nge on which registered Common Stock, $0.001 par value per share KALA The Nasdaq
• $35 million — mpany's listed securities was less than $35 million for the previous 30 consecutive busines
• $2.5 million — have a stockholders' equity of at least $2.5 million or net income from continued operations
• $500,000 — e from continued operations of at least $500,000 in the most recently completed fiscal y

Filing Documents

• kala-20251110x8k.htm (8-K) — 29KB
• 0001104659-25-110316.txt ( ) — 134KB
• kala-20251110.xsd (EX-101.SCH) — 3KB
• kala-20251110_lab.xml (EX-101.LAB) — 15KB
• kala-20251110_pre.xml (EX-101.PRE) — 9KB
• kala-20251110x8k_htm.xml (XML) — 5KB

01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On November 10, 2025, KALA BIO, Inc. (the "Company") received a deficiency letter from the Listing Qualifications Department (the "Staff") of the Nasdaq Stock Market ("Nasdaq") notifying the Company that the listing of its common stock was not in compliance with Nasdaq Listing Rule 5550(b)(2) (the "Minimum MVLS Requirement") for continued listing on The Nasdaq Capital Market, as the market value of the Company's listed securities was less than $35 million for the previous 30 consecutive business days. As of the date of this Current Report on Form 8-K, the Company does not meet the alternative standards for continued listing on The Nasdaq Capital Market, as it does not have a stockholders' equity of at least $2.5 million or net income from continued operations of at least $500,000 in the most recently completed fiscal year or for two of the three most recently completed fiscal years. In accordance with Nasdaq Listing Rule 5810(c)(3)(C), the Company has been provided a period of 180 calendar days, or until May 11, 2026 (the "Compliance Date"), to regain compliance with the Minimum MVLS Requirement. If, at any time before the Compliance Date, the market value of the Company's listed securities closes at $35 million or more for a minimum of 10 consecutive business days, the Staff will provide written notification to the Company that it has regained compliance with the Minimum MVLS Requirement. If the Company does not regain compliance with the Minimum MVLS Requirement by the Compliance Date, the Company will receive written notification that its securities are subject to delisting. At that time, the Company may appeal the Staff's delisting determination to a Nasdaq Listing Qualifications Panel (the "Panel") pursuant to the procedures set forth in the applicable Nasdaq Listing Rules. However, there can be no assurance that, if the Company receives a delisti

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. KALA BIO, INC. Date: November 12, 2025 By: /s/ Mary Reumuth Mary Reumuth Chief Financial Officer and Corporate Secretary

View Full Filing

View this 8-K filing on SEC EDGAR